ES2258642T3 - Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina. - Google Patents

Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.

Info

Publication number
ES2258642T3
ES2258642T3 ES02747793T ES02747793T ES2258642T3 ES 2258642 T3 ES2258642 T3 ES 2258642T3 ES 02747793 T ES02747793 T ES 02747793T ES 02747793 T ES02747793 T ES 02747793T ES 2258642 T3 ES2258642 T3 ES 2258642T3
Authority
ES
Spain
Prior art keywords
alkyl
optionally substituted
alkoxy
phenyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02747793T
Other languages
English (en)
Inventor
Richard AstraZeneca R & D Charnwood EVANS
Matthew AstraZeneca R & D Charnwood PERRY
Brian AstraZeneca R & D Charnwood SPRINGTHORPE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0116179A external-priority patent/GB0116179D0/en
Priority claimed from GB0123037A external-priority patent/GB0123037D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2258642T3 publication Critical patent/ES2258642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Un compuesto de **fórmula** en la que: T es C(O) o S(O)2; W es C(O) o S(O)2; X es CH2, O ó NH; Y es CR5 o N; R1 es arilo opcionalmente sustituido, o heterociclilo opcionalmente sustituido; R2 es hidrógeno, o alquilo C1-6; R3 es hidrógeno, o alquilo C1-6 opcionalmente sustituido; R4 es alquilo, cicloalquilo, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, o heterociclilo opcionalmente sustituido; R5 es hidrógeno, o alquilo C1-6; en los que los restos arilo y heterociclilo anteriores están opcionalmente sustituidos con: halógeno, ciano, nitro, hidroxi, oxo, S(O)pR25, OC(O)NR6R7, NR8R9, NR10C(O)R11, NR12C(O)NR13R14, S(O)2NR15R16, NR17S(O)2R18, C(O)NR19R20, C(O)R21, CO2R22, NR23CO2R24, alquilo C1-6, CF3, alcoxi (C1-6)- alquilo (C1-6), alcoxi C1-6, OCF3, alcoxi (C1-6)- alcoxi (C1-6), alquiltio C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10 (él mismo sustituido opcionalmente con alquilo C1-4 u oxo), metilendioxi, difluorometilendioxi, fenilo, fenil- alquilo (C1-4), fenoxi, feniltio, fenil-alcoxi (C1- 4), heteroarilo, heteroaril-alquilo (C1-4), heteroariloxi o heteroaril-alcoxi (C1-4); en los que cualquiera de los restos fenilo y heteroarilo inmediatamente anteriores están opcionalmente sustituidos con halógeno, hidroxi, nitro, S(O)q(alquilo C1-4), S(O)2NH2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NH(alquilo C1-4), CO2H, CO2(alquilo C1-4), NHC(O)(alquilo C1-4), NHS(O)2(alquilo C1-4), C(O)(alquilo C1-4), CF3 o OCF3.
ES02747793T 2001-07-02 2002-07-01 Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina. Expired - Lifetime ES2258642T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0116179A GB0116179D0 (en) 2001-07-02 2001-07-02 Chemical compounds
GB0116179 2001-07-02
GB0123037 2001-09-25
GB0123037A GB0123037D0 (en) 2001-09-25 2001-09-25 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2258642T3 true ES2258642T3 (es) 2006-09-01

Family

ID=26246268

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02747793T Expired - Lifetime ES2258642T3 (es) 2001-07-02 2002-07-01 Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.

Country Status (26)

Country Link
US (1) US7307090B2 (es)
EP (2) EP1404667B1 (es)
JP (1) JP3857270B2 (es)
KR (1) KR20040013090A (es)
CN (1) CN1545509A (es)
AR (1) AR042401A1 (es)
AT (1) ATE319703T1 (es)
BR (1) BR0210733A (es)
CA (1) CA2452597A1 (es)
CO (1) CO5540307A2 (es)
CY (1) CY1106095T1 (es)
DE (1) DE60209736T2 (es)
DK (1) DK1404667T3 (es)
ES (1) ES2258642T3 (es)
HK (1) HK1062559A1 (es)
HU (1) HUP0401886A2 (es)
IL (1) IL159256A0 (es)
IS (1) IS7094A (es)
MX (1) MXPA03011722A (es)
NO (1) NO20035729L (es)
NZ (1) NZ530202A (es)
PL (1) PL368041A1 (es)
PT (1) PT1404667E (es)
RU (1) RU2004100839A (es)
SA (1) SA02230184B1 (es)
WO (1) WO2003004487A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
WO2003059965A1 (en) * 2002-01-10 2003-07-24 University Of Washington Hydrogels formed by non-covalent linkages
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
SE0200843D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
CA2479362C (en) * 2002-03-21 2011-01-04 Abbott Laboratories N-sulfonylurea apoptosis promoters
US7030115B2 (en) * 2002-03-21 2006-04-18 Abbott Laboratories N-sulfonylurea apoptosis promoters
PE20040167A1 (es) 2002-03-28 2004-05-26 Novartis Ag Amidas del acido sulfamico
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
US20040192738A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0302956D0 (sv) * 2003-11-07 2003-11-07 Astrazeneca Ab Chemical compounds
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
SE0403003D0 (sv) * 2004-12-09 2004-12-09 Astrazeneca Ab Chemical compound 1
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EP1888527A1 (en) * 2005-05-27 2008-02-20 AstraZeneca AB Piperidines for the treatment of chemokine mediated diseases
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
KR20080037655A (ko) 2005-07-21 2008-04-30 아스트라제네카 아베 신규 피페리딘 유도체
EP1957076A2 (en) * 2005-11-29 2008-08-20 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
CN101378756A (zh) * 2006-02-10 2009-03-04 詹森药业有限公司 作为cxcr3受体拮抗剂的哌啶衍生物
JP2009526014A (ja) * 2006-02-10 2009-07-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｘｃｒ３受容体拮抗薬としてのピペリジン誘導体
WO2009038974A1 (en) 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity
CN105001196B (zh) 2008-12-03 2017-05-10 斯克里普斯研究所 干细胞培养
CA3075638A1 (en) 2017-09-25 2019-03-28 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
WO2019136368A2 (en) 2018-01-08 2019-07-11 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
TWI730297B (zh) * 2018-02-27 2021-06-11 日商組合化學工業股份有限公司 巰基酚化合物的製造方法及巰基酚化合物的中間體

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (es) 1969-03-19 1971-10-20
US4556660A (en) 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4588722A (en) 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
US4695575A (en) 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
AU2915892A (en) 1991-11-14 1993-06-15 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
GB9319534D0 (en) 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU5966096A (en) 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
HUP9904622A3 (en) 1996-07-10 2001-07-30 Schering Corp 1,4-di-sustituted piperidines as muscarinic antagonists
EP0821954A1 (en) 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
ATE297381T1 (de) * 1996-08-15 2005-06-15 Schering Corp Ether-muskarinantagonisten
CA2262818A1 (en) 1996-09-10 1998-03-19 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Modified amino acids, pharmaceuticals containing these compounds and methods for their production
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
UA59433C2 (uk) 1998-01-27 2003-09-15 Авентіс Фармасьютікалс Продактс Інк. ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ
JP2002501898A (ja) 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性の環状アミン調節剤
TWI245763B (en) 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
KR20010043032A (ko) 1998-04-28 2001-05-25 도모따께 다께시 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
ES2221399T3 (es) 1998-06-30 2004-12-16 Schering Corporation Antagonistas muscarinicos.
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
WO2000032590A1 (en) 1998-11-25 2000-06-08 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
US6331545B1 (en) 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
HUP0203528A3 (en) * 1999-05-04 2003-11-28 Schering Corp Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
IL147495A0 (en) 1999-07-28 2002-08-14 Aventis Pharm Prod Inc Substituted oxoazaheterocycclyl compounds
IT1307809B1 (it) 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
GB0021670D0 (en) * 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
GB0107907D0 (en) 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
DK1373256T3 (da) 2001-03-29 2005-10-10 Schering Corp CCR5-antagonister, der er nyttige til behandling af AIDS
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300850D0 (sv) 2003-03-25 2003-03-25 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
CA2529161A1 (en) 2003-06-13 2004-12-29 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists

Also Published As

Publication number Publication date
ATE319703T1 (de) 2006-03-15
SA02230184B1 (ar) 2007-03-25
US7307090B2 (en) 2007-12-11
EP1404667B1 (en) 2006-03-08
NZ530202A (en) 2005-06-24
EP1604982A1 (en) 2005-12-14
PL368041A1 (en) 2005-03-21
IS7094A (is) 2003-12-30
RU2004100839A (ru) 2005-06-20
CN1545509A (zh) 2004-11-10
HUP0401886A2 (hu) 2004-12-28
IL159256A0 (en) 2004-06-01
BR0210733A (pt) 2004-07-20
PT1404667E (pt) 2006-07-31
DK1404667T3 (da) 2006-07-10
EP1404667A1 (en) 2004-04-07
JP2004536112A (ja) 2004-12-02
DE60209736D1 (de) 2006-05-04
AR042401A1 (es) 2005-06-22
NO20035729L (no) 2004-02-23
WO2003004487A1 (en) 2003-01-16
KR20040013090A (ko) 2004-02-11
JP3857270B2 (ja) 2006-12-13
MXPA03011722A (es) 2004-03-19
HK1062559A1 (en) 2004-11-12
US20040235894A1 (en) 2004-11-25
DE60209736T2 (de) 2006-11-02
CA2452597A1 (en) 2003-01-16
CY1106095T1 (el) 2011-06-08
CO5540307A2 (es) 2005-07-29
NO20035729D0 (no) 2003-12-19

Similar Documents

Publication Publication Date Title
ES2258642T3 (es) Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
ATE461188T1 (de) Verstärker von glutamat-rezeptoren
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
CO5611135A2 (es) Nuevos derivados de piperidina como moduladores de la actividad de quimioquina, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
MXPA06012595A (es) Analogos de amino-tetrazoles y metodos de uso.
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
AR042273A1 (es) Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen
AR049323A1 (es) Compuestos heterociclicos nitrogenados inhibidores de igf-1r y composiciones farmaceuticas que los componen.
CR8482A (es) Nuevos derivados de quinolina
RS93504A (en) Pyridine compounds or salts thereof and herbicides containing the same
CR9099A (es) Mezclas fungicidas
CO5700801A2 (es) Tratamiento del transtorno por deficit de atencion con hiper actividad
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
AR051392A1 (es) Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
AR041256A1 (es) Indoles sustituidos en posicion 2,4 y su uso como moduladores de 5-ht6
CO6160324A2 (es) Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario
MX2007004274A (es) Quinazolinilmetilentiazolinonas como inhibidores de cdk1.
CO5080761A1 (es) Inhibidores de lad fkbp na inhibidores de las fkbp
DE60220524D1 (de) C-2'-methylierte paclitaxel-derivate zur verwendung als antitumorale mittel
EA200500081A1 (ru) Акутумин и соединения акутумина, синтез и применение
DOP2004001061A (es) Nuevos derivados de quinolina